Scholarlink

Background <p>Chemotherapy-induced neutropenia (CIN) is usually managed by recombinant human granulocyte colony stimulating factor (rhG-CSF) and pegylated rhG-CSF (PEG-rhG-CSF). This study evaluated the efficacy and safety of telpegfilgrastim, a novel Y-shaped PEG-rhG-CSF, for CIN prophylaxis in patients with non-small cell lung cancer (NSCLC).</p> Methods <p>This was a multicentre, randomized, open-label, active-controlled non-inferiority study. Patients with NSCLC who received 1–4 chemotherapy cycles of docetaxel plus carboplatin were randomized 1:1:1 to receive telpegfilgrastim 2&#xa0;mg, 33&#xa0;µg/kg or control drug (rhG-CSF [Topneuter®]&#xa0;in cycle 1 of chemotherapy, rhG-CSF&#xa0;[Topneuter®] or PEG-rhG-CSF&#xa0;[Xinruibai®] per patients’ choice in cycles 2–4 of chemotherapy). The primary endpoint was duration of grade 4 neutropenia in cycle 1 of chemotherapy. Secondary endpoints included duration of grade 4 neutropenia in cycles 2–4 of chemotherapy, incidence of febrile neutropenia (FN), duration and incidence of ≥ grade 3 neutropenia, dynamic change of absolute neutrophil count from baseline and safety.</p> Results <p>From October 16, 2020, to September 1, 2021, 133 patients were randomized to telpegfilgrastim 2&#xa0;mg (<i>n</i> = 44), 33&#xa0;µg/kg (<i>n</i> = 45) and control group (<i>n</i> = 44). In cycle 1 of chemotherapy, the mean duration of grade 4 neutropenia in telpegfilgrastim 2&#xa0;mg, 33&#xa0;µg/kg groups and control group were 0.02&#xa0;day, 0.09&#xa0;day and 0.16&#xa0;day, respectively. The least square mean differences versus control group were -0.14&#xa0;day [95% confidence interval [CI]: -0.35, 0.06] for telpegfilgrastim 2&#xa0;mg group and -0.06&#xa0;day [95% CI: -0.26, 0.15] for telpegfilgrastim 33&#xa0;µg/kg group. which met the prespecified non-inferiority margin of 1&#xa0;day. Incidence of grade 4 neutropenia, incidence of FN and duration of ≥ grade 3 neutropenia in cycles 1–4 of chemotherapy was similar between telpegfilgrastim groups and control group. Telpegfilgrastim was well tolerated, and the incidence of adverse events were comparable with control group.</p> Conclusion <p>This study demonstrated that telpegfilgrastim 2&#xa0;mg or 33&#xa0;μg/kg was non-inferior to rhG-CSF (Topneuter®) and PEG-rhG-CSF (Xinruibai®) for the management of CIN in patients with NSCLC. In particular, a 2&#xa0;mg fixed dose of&#xa0;telpegfilgrastim&#xa0;presents a more convenient administration option.</p> Trial registration <p><a href="https://classic.clinicaltrials.gov/ct2/show/NCT04466137">NCT04466137</a>, July 10, 2020.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月17日

查看全文
  • Yuankai Shi,
  • Xinshuai Wang,
  • Zhidong Pei,
  • Huaqiu Shi,
  • Yanjun Zhang,
  • Tienan Yi,
  • Jiazhuan Mei,
  • Yanzhen Guo,
  • Youhong Dong,
  • Tianjiang Ma,
  • Qingyuan Zhang,
  • Xiaojing Jia,
  • Zhengqiu Zhu,
  • Shen Xu,
  • Yanyan Liu,
  • Hongrui Niu,
  • Weimei Jiang,
  • Xiaodong Jiang,
  • Shengyu Zhou,
  • Li Sun

摘要

Background

Chemotherapy-induced neutropenia (CIN) is usually managed by recombinant human granulocyte colony stimulating factor (rhG-CSF) and pegylated rhG-CSF (PEG-rhG-CSF). This study evaluated the efficacy and safety of telpegfilgrastim, a novel Y-shaped PEG-rhG-CSF, for CIN prophylaxis in patients with non-small cell lung cancer (NSCLC).

Methods

This was a multicentre, randomized, open-label, active-controlled non-inferiority study. Patients with NSCLC who received 1–4 chemotherapy cycles of docetaxel plus carboplatin were randomized 1:1:1 to receive telpegfilgrastim 2 mg, 33 µg/kg or control drug (rhG-CSF [Topneuter®] in cycle 1 of chemotherapy, rhG-CSF [Topneuter®] or PEG-rhG-CSF [Xinruibai®] per patients’ choice in cycles 2–4 of chemotherapy). The primary endpoint was duration of grade 4 neutropenia in cycle 1 of chemotherapy. Secondary endpoints included duration of grade 4 neutropenia in cycles 2–4 of chemotherapy, incidence of febrile neutropenia (FN), duration and incidence of ≥ grade 3 neutropenia, dynamic change of absolute neutrophil count from baseline and safety.

Results

From October 16, 2020, to September 1, 2021, 133 patients were randomized to telpegfilgrastim 2 mg (n = 44), 33 µg/kg (n = 45) and control group (n = 44). In cycle 1 of chemotherapy, the mean duration of grade 4 neutropenia in telpegfilgrastim 2 mg, 33 µg/kg groups and control group were 0.02 day, 0.09 day and 0.16 day, respectively. The least square mean differences versus control group were -0.14 day [95% confidence interval [CI]: -0.35, 0.06] for telpegfilgrastim 2 mg group and -0.06 day [95% CI: -0.26, 0.15] for telpegfilgrastim 33 µg/kg group. which met the prespecified non-inferiority margin of 1 day. Incidence of grade 4 neutropenia, incidence of FN and duration of ≥ grade 3 neutropenia in cycles 1–4 of chemotherapy was similar between telpegfilgrastim groups and control group. Telpegfilgrastim was well tolerated, and the incidence of adverse events were comparable with control group.

Conclusion

This study demonstrated that telpegfilgrastim 2 mg or 33 μg/kg was non-inferior to rhG-CSF (Topneuter®) and PEG-rhG-CSF (Xinruibai®) for the management of CIN in patients with NSCLC. In particular, a 2 mg fixed dose of telpegfilgrastim presents a more convenient administration option.

Trial registration

NCT04466137, July 10, 2020.